What is Superantigen?
Superantigen is a powerful immune cell activator. It’s developed from a complicated protein source. During the process of immune response, it can activate immune cells, such as T-cells , NK-cells, LAK-cells at speeds of 2,000-50,000 times normal activation rates. It produces interleukin, interferon, tumor cell necrosis and other cytokines.
Superantigen , specifically SEC (Staphylococcal Enterotoxin C) or HAS (Highly Agglutinative Staphylococcal) in it’s original form (as discovered by Dr White from Howard Hughes Medical Institute) was found to exhibit toxic reactions, however Chinese medical research teams from Xiehe Group as far back as 2 & half decades ago developed and patented a mutated non-toxic Superantigen or SEC for safe use by humans.
Clinical trials have been done on patients with many forms of cancers including : Leukemia, Glioma (brain tumor), Cervical cancer, cervical lymph node metastatic tumors, Metastatic carcinoma, Hepatocellular carcinoma (liver cancer) , Nasopharyngeal carcinoma, Lung Cancer, non-small cell lung cancer, pleural effusion, gastric cancer, breast cancer, bone marrow cancer, lymphoma, malignant mesothelioma, esophageal carcinoma, colorectal tumors, oral cancer, ovarian tumor, etc.
Radiation and chemotherapy users can alleviate up to 80% of symptoms.
Who are we:
Click Here to view summary results
Click here to view samples of published clinical trial results
2016: Recently President Chen of Xiehe met with Prof Dongfeng Tan of MD Anderson Cancer Clinic to discuss clinical application of Superantigen in cancer treatments.
Our (Xiehe) 2016 international immunology conference in Changxing, China was attended by nobel prize winners Ferid Murad and Rolf Zinkernagel. See TV channel news report (apologies for non-Chinese speakers) Chinese TV broadcast
UltimateCure has global distribution rights to Xiehe Group Products and deal directly with clinics or Physicians.
Risks and Side effects: Products supplied by us have not been tested on pregnant women or infants.
Contact Us via email or call Paul +27 82 573 5656